1
|
Liu JR, Wu WJ, Liu SX, Zuo LF, Wang Y, Yang JZ, Nan YM. Nimesulide inhibits the growth of human esophageal carcinoma cells by inactivating the JAK2/STAT3 pathway. Pathol Res Pract 2015; 211:426-34. [PMID: 25724470 DOI: 10.1016/j.prp.2015.01.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 01/02/2015] [Accepted: 01/19/2015] [Indexed: 01/15/2023]
Abstract
Although selective COX-2 inhibitors have cancer-preventive effects and induce apoptosis, the mechanisms underlying these effects are not fully understood. This study investigated the effects of nimesulide, a selective COX-2 inhibitor, on apoptosis and on the JAK/STAT signaling pathway in Eca-109 human esophageal squamous carcinoma cells. The effects and mechanisms of nimesulide on Eca-109 cell growth were studied in culture and in nude mice with Eca-109 xenografts. Cells were cultured with or without nimesulide and/or the JAK2 inhibitor AG490. Cell proliferation was evaluated using the MTT assay, and apoptosis was investigated. COX-2 mRNA expression was measured using reverse transcription polymerase chain reaction, and protein expression was detected by Western blot analysis, immunohistochemistry, and flow cytometry. Nimesulide significantly inhibited Eca-109 cell viability in vitro in a dose- and time-dependent manner (P<0.05). Nimesulide also induced apoptosis, which was accompanied by a significant decrease in the expression of COX-2 and survivin and an increase in caspase-3 expression. Nimesulide downregulated the phosphorylation levels of JAK2 and STAT3, and JAK2 inhibition by AG490 significantly augmented both nimesulide-induced apoptosis and the downregulation of COX-2 and survivin (P<0.05). In vivo, nimesulide inhibited the growth of Eca-109 tumors and the expression of p-JAK2 and p-STAT3. Thus, nimesulide downregulates COX-2 and survivin expression and upregulates caspase-3 expression in Eca-109 cells, by inactivating the JAK2/STAT3 pathway. These effects may mediate nimesulide-induced apoptosis and growth inhibition in Eca-109 cells in vitro and in vivo.
Collapse
Affiliation(s)
- Jun-Ru Liu
- Department of Pathology, The University of Hongkong-Shenzhen Hospital, Shenzhen, China.
| | - Wen-Juan Wu
- Department of Radiology, Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Shu-Xia Liu
- Department of Pathology, Hebei Medical University, Shijiazhuang, China
| | - Lian-Fu Zuo
- Hebei Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yuan Wang
- Department of Endocrinology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jian-Zhu Yang
- Department of Pathology, Third Hospital of Hebei Medical University, Shijiazhuang, China
| | - Yue-Min Nan
- Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
2
|
Liu JF, Zhang SW, Jamieson GG, Zhu GJ, Wu TC, Zhu TN, Shan BE, Drew PA. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Int J Cancer 2007; 122:1639-44. [DOI: 10.1002/ijc.23288] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
3
|
Liu JF, Jamieson GG, Drew PA, Zhu GJ, Zhang SW, Zhu TN, Shan BE, Wang QZ. Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-kappaB downstream regulation of cyclooxygenase-2. ANZ J Surg 2006; 75:1011-6. [PMID: 16336399 DOI: 10.1111/j.1445-2197.2005.03596.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
BACKGROUND Aspirin has potential in the prevention or treatment of oesophageal cancer, the seventh most common cancer in the world, but its mechanism of action is still not certain. METHODS The oesophageal squamous cell carcinoma cell line TE-13 was cultured with aspirin at different concentrations or for different times. Proliferation and apoptosis were measured by MTT reduction and flow cytometry. Expression of COX-2 mRNA was measured by RT-PCR and COX-2 protein levels with Western blot analysis. Nuclear NF-kappaB and cytoplasmic IkappaB protein levels were determined by electrophoretic mobility shift assay and Western blot, respectively. RESULTS Aspirin significantly inhibited cell proliferation and induced apoptosis at concentrations of 1, 4, 8 mmol/L. Aspirin dose-dependently decreased the levels of COX-2 mRNA, COX-2 protein and nuclear NF-kappaB protein and increased the cytoplasmic IkappaB protein. CONCLUSION We conclude that aspirin inhibits the proliferation of, and induced apoptosis in, the cultured TE-13 SCC cell line. These changes correlate with a reduction in COX-2 mRNA and protein expression, prostaglandin synthesis, an inhibition of NF-kappaB nuclear translocation, and an increase in cytoplasmic IkappaB. These results support the further investigation of the cyclooxygenase pathway in investigating the potential of aspirin and similar drugs in cancer prevention and therapy.
Collapse
Affiliation(s)
- Jun-Feng Liu
- Department of Thoracic Surgery, Fourth Hospital, Hebei Medical University, Shijiazhuang, China.
| | | | | | | | | | | | | | | |
Collapse
|
4
|
Plaisant N, Senesse P, Azria D, Lemanski C, Ychou M, Quenet F, Saint-Aubert B, Rouanet P. Surgery for Esophageal Cancer after Concomitant Radiochemotherapy: Oncologic and Functional Results. World J Surg 2004; 29:32-8. [PMID: 15592917 DOI: 10.1007/s00268-004-7455-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The aim of this study was to evaluate the results of surgery after preoperative radiochemotherapy (PRCT) for esophageal cancer. This retrospective study included 88 patients scan between 1992 and 2000. The median follow-up was 55.7 months (3.3-104.1 months). Surgical mortality was 15.9%. Multivariate analysis found that the following were risk factors for surgical mortality: gamma-glutamyltransferase level > 75 UI/ml (p = 0.007), weight loss = 10% (p = 0.05), and digestive toxicity World Health Organization grade III or IV during PRCT (p = 0.019). The median overall survival was 24.9 months. The 5-year overall survival (OS) and disease-free survival (DFS) were, respectively, 33.1% and 33.2%. Complete responder patients had a 71.8% 5-year OS (p = 0.01) and a 71.8% 5-year DFS (p = 0.009). The rate of recurrence was 37.5%. Multivariate analysis found that female gender (p = 0.03), weight loss = 10% (p = 0.03), preoperative computed tomography scan bronchial contact (p = 0.01), and N+ status (pN+) at pathology examination (p = 0.0001) were predictors of poor oncologic results. Patients with high preoperative risk of surgical mortality need to be selected for intensive perioperative management. In association with surgery, PRCT improves the local control, DFS, and OS of responder patients. Morphologic evaluation for staging esophageal cancer in predicting the pathologic response after PRCT is poor or controversial. Only surgical resection can provide accurate prognostic information for staging esophageal cancer and improving local control.
Collapse
Affiliation(s)
- Nicolas Plaisant
- Department of Surgical Oncology, Centre Regional de Lutte Centre le Cancer, 208 Rue des Apothicaires, Parc Euromedecine, 34298 Montpellier Cedex 5, France.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
van Sandick JW, van Lanschot JJB, ten Kate FJW, Tijssen JGP, Obertop H. Indicators of prognosis after transhiatal esophageal resection without thoracotomy for cancer. J Am Coll Surg 2002; 194:28-36. [PMID: 11803954 DOI: 10.1016/s1072-7515(01)01119-x] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
BACKGROUND Various techniques have been described for the surgical treatment of esophageal cancer. The transhiatal approach has been debated for its safety and oncologic results. STUDY DESIGN Between January 1993 and September 1996, 115 patients underwent a transhiatal esophagectomy with curative intent for adenocarcinoma or squamous cell carcinoma of the middle or distal esophagus or esophagogastric junction. Procedure-related hazards, pathologic results, and prognostic factors for survival were evaluated. Median duration of postoperative followup was 27 months (range 1 to 74 months) for all patients and 45 months (range 30 to 74 months) for those alive at final followup. RESULTS No emergency thoracotomies were experienced. In-hospital mortality was 3.5%. Vocal cord dysfunction (24%) and pulmonary complications (23%) were the most frequent early postoperative complications. A microscopically radical resection was achieved in 73% of patients. Overall survival was 45% at 3 years. In univariate analysis, the most pronounced indicators of longterm survival (p < 0.0001) were radicality of the resection, lymph node involvement, lymph node ratio (ie, the ratio of invaded to removed lymph nodes), and pathologic tumor stage. Multivariate analysis identified the lymph node ratio (p < 0.0001) as the strongest independent predictor of long-term survival, followed by radicality of the resection (p = 0.0064) and duration of ICU stay (p = 0.027). CONCLUSION Transhiatal esophagectomy without thoracotomy can be considered a safe procedure for resectable cancer of the midesophagus, distal esophagus, or esophagogastric junction. Radicality and survival results were in line with the data reported for traditional transthoracic approaches. A prognostic value of the lymph node ratio was observed. It emphasizes the need for controlled trials aimed at delineating the prognostic impact of an extended lymph node dissection.
Collapse
Affiliation(s)
- Johanna W van Sandick
- Department of Surgery, Academic Medical Center, University of Amsterdam, The Netherlands
| | | | | | | | | |
Collapse
|
6
|
Grannell MS, Kelly S, Shannon S, Chong AL, Walsh TN. The sinister significance of dysphagia. Ir J Med Sci 2001; 170:244-5. [PMID: 11918330 DOI: 10.1007/bf03167788] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The majority of patients presenting with oesophageal cancer have symptoms for more than three months and advanced disease at presentation. Most appear unaware of the significance of dysphagia as a symptom. Cancer awareness programmes focus on symptoms such as lumps and bleeding. AIM To sample the level of public awareness of the potentially sinister significance of the symptom of dysphagia. METHODS A community survey was conducted using a questionnaire to evaluate the subjects' impression of the significance of dysphagia, and compare it with their perception of the significance of breast lump. Patients were stratified to male and female, under and over 45 years. RESULTS There were 164 subjects interviewed. Seventy-five per cent stated that they would visit their doctor within one week of developing dysphagia compared with 87 per cent questioned about a breast lump (96 per cent females, 80 per cent males). Only 17 per cent felt that cancer was a probable explanation for dysphagia compared with 80 per cent who would consider cancer a likely cause of breast lump. CONCLUSION There is evident need of an awareness programme of the potential significance of dysphagia if prognosis for oesophageal cancer is to be improved.
Collapse
Affiliation(s)
- M S Grannell
- James Connolly Memorial Hospital, Blanchardstown, Dublin
| | | | | | | | | |
Collapse
|
7
|
Meneu-Diaz JC, Blazquez LA, Vicente E, Nuño J, Quijano Y, Lopez-Hervás P, Devesa M, Fresneda V. The role of multimodality therapy for resectable esophageal cancer. Am J Surg 2000; 179:508-13. [PMID: 11004342 DOI: 10.1016/s0002-9610(00)00384-6] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND There is an increasing interest in the role of combined therapy to achieve long-term survival for patients with resectable esophageal neoplasms. Surgery provides excellent palliation with relatively low morbidity and mortality rates, but cure remains elusive. MATERIAL AND METHODS From January 1988 to January 1998, a total of 137 patients met eligibility criteria for a combined multimodal therapy, prospective, nonrandomized protocol of induction chemoradiation therapy followed by surgical resection, based on radiological and endoscopic assessment of the extension (all patients were initially considered to be at clinical stages I to III, locoregional). Consequently, patients with high grade Barrett's dysplasia or any squamous carcinoma in situ (stage 0) and those with distant metastatic disease (stage IV) were excluded. Among this group, 48 operable patients with biopsy-proven esophageal cancer finally entered and completed the protocol and are the sample of the present study. Multivariate logistic regression models were used to identify risk factors for death or recurrence. Actuarial survival was calculated since the beginning of the induction protocol by the Kaplan-Meier method, and comparisons between groups were made by the log-rank test. RESULTS Mean age was 61.6 (range 45 to 71), and 72.9% were male. The majority of the tumors (70.8%) were located at the lower third/cardia and as many as 18.8% were adenocarcinoma. After a mean of 7.5 weeks (range 5 to 12) after the completion of the induction phase, 68.7% underwent a transthoracic esophagectomy and 31.3% a transhiatal esophagectomy. The in-hospital mortality rate was 10.4% (5 patients). A complete response (no evidence of tumor within the specimen: pT0) was achieved in 25% (12 patients). After a mean follow-up of 20.2 months, mean survival for the entire group was 18.2 months (95% confidence interval 14 to 22). At the end of the study, 25% (12) remained alive. Actuarial survival rates at 12, 23, and 37 months were 56.2%, 36.9%, and 21.9%, respectively. CONCLUSIONS Esophageal resection after induction therapy seems to be related to a slightly higher mortality rate compared with historical series, and for this reason, neoadjuvant therapy must be considered still experimental. However, no statistical significant difference in survival is showed in those cases with complete pathological response (pT0). Factors influencing survival are recurrence and age. Surgery alone remains the standard therapy for esophageal cancer.
Collapse
Affiliation(s)
- J C Meneu-Diaz
- Departamento de Cirugía General y del Aparato Digestivo, Hospital Universitario Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Torres AJ, Sánchez-Pernaute A, Hernando F, Díez Valladares L, González López O, Pérez Aguirre E, Suárez A, Balibrea JL. Two-field radical lymphadenectomy in the treatment of esophageal carcinoma. Dis Esophagus 1999; 12:137-43. [PMID: 10466047 DOI: 10.1046/j.1442-2050.1999.00037.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
This paper retrospectively compares post-operative complications, mortality and long-term survival of patients with esophageal carcinoma who were treated with standard esophagectomy or with extended two-field lymph node clearance. Fifty-seven patients with resectable esophageal carcinoma were included in the study. Twenty-eight patients were submitted to a radical two-field esophagectomy and lymphadenectomy, while the remaining 29 were submitted to a standard, more conservative, esophagectomy performed mostly through a transhiatal route. The two groups of patients were similar in all clinical, laboratory and pathologic features. There was a significant lower anastomotic leakage rate in the group of patients submitted to a radical lymph node resection; post-operative respiratory complication rate and mortality were similar in both groups. The overall 5-year survival was 20%. When lymph node resection was performed, the 5-year survival rate rose to 36%; it was 44% when nodal involvement was negative and 19% for N1 patients; when standard esophagectomy was the procedure, these figures were 9% (p < 0.05), and 6% respectively.
Collapse
Affiliation(s)
- A J Torres
- II Department of Surgery, Hospital Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Alexiou C, Beggs D, Salama FD, Brackenbury ET, Morgan WE. Surgery for esophageal cancer in elderly patients: the view from Nottingham. J Thorac Cardiovasc Surg 1998; 116:545-53. [PMID: 9766581 DOI: 10.1016/s0022-5223(98)70159-x] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
OBJECTIVE Our aim was to compare the outcome of esophageal resection for carcinoma in elderly patients (aged over 70 and over 80 years) with that of younger patients managed within a single specialist thoracic surgery unit. PATIENTS AND METHODS Between January 1987 and November 1997, 523 patients underwent esophagectomy for carcinoma in the Nottingham City Hospital Thoracic Surgery Unit. The patients were divided into 3 groups by age: group I, under 70 years (n = 337); group II, 70 to 79 years (n = 150), and group III, 80 to 86 years (n = 36). These groups were compared with regard to preoperative medical status, operability and resectability, complications, operative mortality, and longterm survival. RESULTS Patients in groups II (6.0%) and III (2.8%) had fewer preexisting respiratory problems than patients in group I (12.5%), and the patients in group III had fewer preexisting cardiovascular problems (16.7%) than patients in groups I (25.2%) and II (32.7 %). Although patients in group III were generally less likely to have operable lesions (64.3%), no significant differences in resectability rate were detected among the 3 groups (80.8%, 77.7%, and 80%). Elderly patients (groups II and III) had a higher incidence of overall (34% and 36.1%), respiratory (24.7% and 19.4%), and cardiovascular (7.3% and 11.1%) complications than those aged under 70 years (24.6%, 16.3%, and 2.1%, respectively). However, operative mortality (4.7%, 6.7%, and 5.6%) and 5-year survivals inclusive of operative mortality (25.1%, 21.2%, and 19.8%) were similar among the 3 groups. CONCLUSIONS Accumulated experience in all aspects of perioperative management may account for a low hospital mortality in elderly patients despite a greater operative risk. The survival benefit is similar to that in the younger age groups, enforcing the view that esophagectomy within specialist thoracic units can be safely offered (in appropriately selected patients) with acceptable long-term survival in all age groups.
Collapse
Affiliation(s)
- C Alexiou
- Thoracic Surgery Unit, Nottingham City Hospital, Nottingham, United Kingdom
| | | | | | | | | |
Collapse
|
10
|
Wobst A, Audisio RA, Colleoni M, Geraghty JG. Oesophageal cancer treatment: studies, strategies and facts. Ann Oncol 1998; 9:951-62. [PMID: 9818067 DOI: 10.1023/a:1008273110272] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Esophageal cancer is among the ten most frequent cancers in the world. Once diagnosis is established prognosis is poor with five-year survival rates below 10%. Over the last few years, the evidence--base for treatment of oesophageal cancer has changed with the publication of several important articles in this field. This article reviews these and other relevant publications with focus on current evidence which holds potential for an improvement in survival in oesophageal cancer patients. Prevention and early detection represent the mainstay in the ongoing struggle to improve prognosis, which is most stringently linked to tumor stage. Other efforts have been dedicated to optimise surgical treatment, radiotherapy and chemotherapy and to discover the most efficient combinations of these treatment modalities. Strong but not unanimous evidence in favour of a multimodality approach with chemoradiotherapy followed by surgery has accumulated in recent years, and confirmatory trials are presently ongoing. A pathological complete response to chemoradiotherapy has been identified to significantly enhance survival. Among the strategies to achieve higher response rates, variations in the administration of the most commonly used drugs rather than higher drug and radiation dosages seem promising. Occult lymphatic spread has been recognized as a major source of recurrence and has been successfully targeted by three field surgical dissection and extended field radiotherapy. In search of the optimal treatment for patients with oesophageal cancer, a variety of different tracks are being pursued. This review outlines and analyses current treatment approaches and investigates how recent advances may impact on patient management.
Collapse
Affiliation(s)
- A Wobst
- Department of Surgery, European Institute of Oncology, Milan, Italy
| | | | | | | |
Collapse
|